Compare Page
Hexarelin vs GHRP-2
Quick verdict: Hexarelin and GHRP-2 are both potent growth hormone releasing peptides from the same GHRP class, but they occupy different positions on the potency-selectivity spectrum. Hexarelin delivers the highest peak GH output of any GHRP and uniquely binds cardiac CD36 receptors, but shows the strongest cortisol/prolactin co-stimulation and fastest tachyphylaxis. GHRP-2 offers a more balanced profile — strong GH release with more manageable hormonal side effects and better sustained responsiveness over time.
Read the full peptide profiles: Hexarelin | GHRP-2.
At a Glance: Hexarelin vs GHRP-2
Mechanism of Action
Hexarelin and GHRP-2 are both synthetic hexapeptide growth hormone secretagogues that bind the ghrelin receptor (GHS-R1a) on anterior pituitary somatotrophs to stimulate pulsatile GH release. They belong to the same peptide class and share the same primary target, but their pharmacological fingerprints differ in important ways. Hexarelin is consistently the most potent GHRP for peak GH elevation, producing the largest acute GH pulses of any peptide in the class. However, this potency extends to non-selective effects — Hexarelin also produces the strongest cortisol and prolactin co-stimulation among GHRPs, reflecting broader activation of hypothalamic-pituitary pathways beyond the GH axis.
GHRP-2 occupies a more balanced pharmacological position. It produces robust GH release — typically ranked second to Hexarelin in peak output — but with moderately less cortisol and prolactin elevation. GHRP-2 also stimulates appetite through ghrelin-mimetic hypothalamic activity, though somewhat less aggressively than GHRP-6. The practical result is that GHRP-2 delivers strong GH stimulation with a more tolerable hormonal side-effect profile than Hexarelin, making it a workhorse secretagogue in many research protocols.
The distinguishing mechanistic feature of Hexarelin is its binding to CD36 (scavenger receptor class B) on cardiac tissue. This interaction, independent of GHS-R1a and GH release, produces cardioprotective effects including reduction of cardiac fibrosis, protection against ischaemia-reperfusion injury, and anti-apoptotic signalling in cardiomyocytes. GHRP-2 does not share this CD36 mechanism, making Hexarelin uniquely positioned for cardiac research applications beyond the GH secretagogue paradigm. For comparisons across the full GHRP spectrum, see GHRP-6 vs Hexarelin, GHRP-2 vs GHRP-6, and Hexarelin vs Ipamorelin.
Research Evidence
GHRP-2 has one of the most extensive research portfolios in the secretagogue class, with pharmacological characterisation spanning GH dose-response curves, hormonal cross-reactivity profiling, and diagnostic applications for GH deficiency testing. Its GH-releasing potency has been validated in numerous human pharmacokinetic studies, and it has been used as a diagnostic challenge test for GH axis assessment — the GHRP-2 stimulation test is employed in clinical endocrinology to evaluate pituitary GH reserve. This diagnostic utility provides a breadth of human pharmacological data that most peptides lack.
Hexarelin’s research trajectory has been more focused on two distinct areas: acute GH-release pharmacology and cardiac biology. The cardiac research strand is unique to Hexarelin — Locatelli et al. demonstrated that Hexarelin’s cardioprotective effects persist even when GH release is pharmacologically blocked, confirming the GH-independent CD36 mechanism. In cardiac ischaemia-reperfusion models, Hexarelin reduced infarct size, decreased cardiac apoptosis, and protected mitochondrial function. Clinically, Hexarelin has been tested in healthy volunteers and GH-deficient patients, confirming its superior peak GH output and documenting its tachyphylaxis liability.
The evidence landscape positions these peptides differently: GHRP-2 is the more practical research tool for sustained GH investigation (better tolerance, maintained responsiveness, diagnostic applications). Hexarelin is the more specialised tool — maximum acute GH power plus unique cardiac biology. Researchers needing chronic GH stimulation generally prefer GHRP-2; those investigating cardiac physiology or requiring maximal acute GH challenge prefer Hexarelin. Both share the limitation of non-selectivity relative to Ipamorelin (see GHRP-2 vs Ipamorelin).
Key Differences
- GH peak potency: Hexarelin produces higher peak GH concentrations; GHRP-2 is a close second but with modestly lower maximal output
- CD36 cardiac mechanism: Hexarelin uniquely binds CD36 scavenger receptors for GH-independent cardioprotection; GHRP-2 does not share this mechanism
- Tachyphylaxis: Hexarelin shows faster and more pronounced GH response attenuation with chronic dosing; GHRP-2 maintains more consistent responses over time
- Cortisol/prolactin elevation: Both raise cortisol and prolactin, but Hexarelin’s co-stimulation is more pronounced than GHRP-2’s
- Half-life: Hexarelin has a longer half-life (~70 min vs ~25–30 min), influencing dosing frequency in research protocols
- Diagnostic utility: GHRP-2 is used clinically as a GH stimulation test for diagnosing GH deficiency; Hexarelin is not commonly used diagnostically
Frequently Asked Questions
Which GHRP releases the most growth hormone?
Hexarelin consistently produces the highest peak GH concentration of any GHRP in comparative pharmacological studies, followed closely by GHRP-2, then GHRP-6. Ipamorelin produces the lowest peak GH of the major secretagogues but compensates with unmatched selectivity. For maximum acute GH, Hexarelin is the strongest option — but this comes with the most pronounced cortisol and prolactin co-stimulation.
Why might GHRP-2 be preferred over Hexarelin for chronic research?
GHRP-2 maintains its GH-releasing efficacy more consistently over repeated dosing compared to Hexarelin, which shows progressive tachyphylaxis (diminishing GH response). GHRP-2 also produces less cortisol and prolactin elevation per unit of GH released, giving it a better ratio of desired to undesired effects. For research protocols requiring sustained GH stimulation over weeks or months, GHRP-2’s more reliable responsiveness makes it the more practical choice.
Is Hexarelin’s cardioprotective effect clinically significant?
In preclinical models, Hexarelin’s CD36-mediated cardiac effects are substantial — reduced infarct size, decreased cardiac apoptosis, and protection against ischaemia-reperfusion injury. These effects occur independently of GH release, confirming a distinct pharmacological action. However, clinical translation of these cardiac findings to human therapy has not progressed beyond early-stage research. The cardioprotective mechanism is real and well-documented in animal models, but human clinical cardiac data remains limited.
Does GHRP-2 stimulate appetite like GHRP-6?
GHRP-2 does stimulate appetite through its ghrelin-mimetic activity, but the effect is less pronounced than with GHRP-6, which produces the strongest appetite stimulation of any GHRP. Hexarelin’s appetite effects are generally considered milder than both GHRP-2 and GHRP-6. If appetite stimulation needs to be minimised while maintaining strong GH release, Ipamorelin is the preferred option (see GHRP-2 vs Ipamorelin).
Can either peptide be combined with GHRH analogs?
Both Hexarelin and GHRP-2 synergise powerfully with GHRH analogs such as CJC-1295 and Sermorelin. The synergy occurs because GHRPs (ghrelin pathway) and GHRH analogs (GHRH receptor pathway) stimulate GH through independent receptor mechanisms on the somatotroph cell. The combined GH output typically exceeds the sum of individual effects. GHRP-2 is more commonly chosen for combination protocols due to its better sustained responsiveness and more manageable side-effect profile. See CJC-1295 vs GHRP-2.
Are both peptides used for diagnosing GH deficiency?
GHRP-2 has been validated as a clinical GH stimulation test for diagnosing GH deficiency, particularly in Japan and some European countries. The GHRP-2 stimulation test involves a standardised subcutaneous injection followed by serial GH measurements. Hexarelin has been used similarly in research settings, but GHRP-2 has more standardised clinical protocols and reference ranges established for diagnostic interpretation.
How do Hexarelin and GHRP-2 compare to the selective secretagogue Ipamorelin?
Both Hexarelin and GHRP-2 produce higher peak GH levels than Ipamorelin, but both also elevate cortisol and prolactin — effects Ipamorelin avoids entirely. The GHRP family represents a potency-selectivity trade-off: Hexarelin (most potent, least selective) → GHRP-2 (balanced) → Ipamorelin (most selective, lowest peak GH). The choice depends on whether maximum GH amplitude, balanced utility, or hormonal cleanliness is the research priority.
References
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
- Bodart V, Febbraio M, Bhogendra RJ, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484
- Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PMID: 10465271
- Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 11238504
- Aimaretti G, Baffoni C, DiVito L, et al. Comparisons among old and new provocative tests of GH secretion in 178 normal adults. Eur J Endocrinol. 2000;142(4):347-352. PMID: 10754475
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9893709